Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Fusion IP plc    FIP   GB00B05L5X50

No quotes available
-- GBp   0.00%
2014 FUSION IP : Court Confirmation of Capital Reduction and Effective Da..
2014 FUSION IP : Exercise of Options
2014 FUSION IP : Rule 2.10 Announcement
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Fusion IP plc : Simcyp develops virtual laboratory mouse for use in cancer and toxicology research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/19/2012 | 11:07am CEST

Sheffield, UK. 18th January 2012. Simcyp Limited , the leader in modelling and simulation of drug-drug interactions in virtual human populations, today announces it has extended its animal models to include a virtual mouse.

Laboratory mice are used extensively in the development of new anti-cancer drugs as well as toxicological studies involving agrochemicals.  This research often involves using mice which have been genetically modified in order to investigate the role that drug metabolising enzymes and transporters play in the accumlation of drugs in the whole animal or in specific tissues.  The Simcyp Mouse provides a virtual environment for evaluating drug disposition which will replace the need for some live animal testing in normal as well as transgenic mice, thus reducing and refining preclinical investigation.

The Simcyp Simulators are mathmatical models linking numerous physiological, genetic and biochemical databases with drug-specific data to produce "real-life" predictions to help optimise drug development.  The ability to create virtual transgenic mice by adding (knocking-in) or deleting (knocking-out) certain genes is a unique feature of this model.

Dr Steve Toon, Executive Director at Simcyp, commented:  "The Simcyp Mouse Simulator is a valuable addition to our portfolio of virtual animal models.  Simcyp Mouse will be an incredibly useful tool for scientists and clinicians developing new anti-cancer drugs helping reduce cost, accelerate development timelines and reduce animal testing.  I am proud that Simcyp is able to make its own contribution to the advancement of cancer research."

Members of the Simcyp Consortium of leading pharmaceutical and biotechnology companies have automatic access to all of Simcyp's preclinical models with the latest release of the Simcyp Population-based Simulator.  Licenses for Simcyp Animal can now also be granted to companies outside of the Consortium including contract research organisations.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FUSION IP PLC
2014 FUSION IP : Court Confirmation of Capital Reduction and Effective Date
2014 FUSION IP : Exercise of Options
2014 FUSION IP : Rule 2.10 Announcement
2014 FUSION IP PLC : Rule 2.0 Announcement
2014 FUSION IP PLC : Results of the Court Meeting and General Meeting
2014 FUSION IP PLC : Further announcement 24th February – Scheme Document
2014 FUSION IP PLC : Fusion portfolio company Asalus awarded CE mark for Ultravision
2013 FUSION IP PLC : Phase Focus strengthens Board with New Chairman and Directors
2013 FUSION IP PLC : Absynth Biologics Limited secures £850,000 funding to develop it..
2013 FUSION IP PLC : Fusion portfolio company MedaPhor expands sales into China throu..
More news
Sector news : Venture Capital
07/29 Monte dei Paschi approves privately-backed rescue plan
07/29 U.S. private equities behind UBS-Passera plan for Monte dei Paschi - source
07/29 Aberdeen Asset Management says will vote against SABMiller, AbInbev deal
07/29 UBS : scraps return targets on volatility after second-quarter profit beat
07/29DJNextEra to Buy Energy Future's Oncor in $18.4 Billion Deal
More sector news : Venture Capital
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Peter Leonard Grant Executive Director & Operations Director
David Michael Davies Non-Executive Director
David Graham Baynes Executive Director
Robert Rabone Non-Executive Director
David John Catton Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FUSION IP PLC0.00%0
BLACKROCK, INC.7.56%59 833
UBS GROUP AG0.00%52 984
GOLDMAN SACHS BDC INC5.68%50 224
BANK OF NEW YORK MELLO..-4.42%42 437
STATE STREET CORP-0.87%26 045
More Results